What is the best Selective Serotonin Reuptake Inhibitor (SSRI) for pregnant women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best SSRI for Pregnant Women

Sertraline should be considered the first-line SSRI for pregnant women due to its minimal excretion in breast milk, low infant-to-maternal plasma concentration ratios, and favorable safety profile throughout pregnancy and lactation. 1

Primary Recommendation

  • The American Academy of Pediatrics specifically recommends sertraline as first-line therapy for pregnant and breastfeeding women requiring SSRI treatment. 1
  • Sertraline provides infants with less than 10% of the maternal daily dose through breast milk, making it one of the safest options for continuation during lactation. 1, 2
  • Large population-based studies have demonstrated no increased risk of cardiac malformations with first-trimester sertraline use. 1

Alternative Option

  • Citalopram should be considered as the alternative if sertraline is not tolerated or ineffective. 1
  • Paroxetine should be specifically avoided due to FDA pregnancy category D classification and documented concerns regarding cardiac malformations. 1

Dosing Strategy

  • Start with the lowest effective dose (25-50 mg daily for sertraline) and titrate slowly upward as needed. 1
  • Continue treatment throughout pregnancy rather than discontinuing, as withdrawal carries significant risks to the mother-infant dyad. 1, 2
  • Maintain treatment at the lowest effective dose throughout all trimesters. 1, 2

Important Risks to Discuss

Third-Trimester Exposure:

  • Approximately one-third of exposed newborns may develop neonatal adaptation syndrome with symptoms including irritability, jitteriness, tremors, feeding difficulty, sleep disturbance, and respiratory distress. 1, 2
  • These symptoms typically appear within hours to days after birth and usually resolve within 1-2 weeks without intervention. 1, 2
  • A possible association exists with persistent pulmonary hypertension of the newborn (PPHN), though the absolute risk is small with a number needed to harm of 286-351. 1, 2

Monitoring Requirements:

  • Arrange for early follow-up after initial hospital discharge for infants exposed to SSRIs in the third trimester. 1
  • Monitor infants for signs of drug toxicity or withdrawal over the first week of life, ideally for at least 48 hours after birth. 1, 2
  • In severely affected infants with persistent symptoms, a short-term course of chlorpromazine has provided measurable relief. 1

Critical Clinical Context

  • Untreated depression during pregnancy carries substantial documented risks including premature birth, decreased breastfeeding initiation, and harm to the mother-infant relationship. 1, 3
  • Women who discontinue antidepressants during pregnancy show significant increases in relapse of major depression. 2
  • The benefits of continuing SSRI treatment typically outweigh the risks when maternal depression requires pharmacological management. 1, 4

Common Pitfall to Avoid

  • Do not discontinue sertraline due to fear of medication risks, as untreated maternal depression poses greater documented harm to both mother and infant than the potential risks of sertraline exposure. 1
  • Women already taking sertraline who become pregnant should continue the medication if clinically indicated rather than abruptly stopping. 3, 2

References

Guideline

SSRI Use During Pregnancy and Postpartum Period

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Risks of SSRIs During Pregnancy on Neonatal Transition

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safety of Sertraline During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.